Literature DB >> 2838642

Receptor for plasmin on human carcinoma cells.

P Burtin1, M C Fondaneche.   

Abstract

We have shown that cells from human tumor cell line SW 1116 have receptors for plasmin and plasminogen. These receptors are the same for the proenzyme and the enzyme, but they have a much higher affinity for plasmin (Kd = 6 X 10(-8) M) than for plasminogen (Kd = 5 X 10(-6) M). Plasminogen binding was strongly increased by preincubation of the tumor cells with urokinase and was inhibited by anti-urokinase serum. Because free plasmin is rapidly neutralized in vivo, it is likely that, under physiological conditions, plasminogen is bound by tumor cells and partially transformed into plasmin by urokinase already present at the surface of these cells. Bound plasmin retains its enzymatic activity, which demonstrates that its binding does not involve the enzyme's active site.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838642     DOI: 10.1093/jnci/80.10.762

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Cell signalling associated with fibrinolytic ligand binding to human colorectal carcinoma cells.

Authors:  V Liepkalns; H Durand; C Bougeret
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

Review 3.  The invasive phenotypes.

Authors:  M M Mareel; F M Van Roy; P De Baetselier
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

Review 4.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

5.  Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.

Authors:  J Pöllänen; A Vaheri; H Tapiovaara; E Riley; K Bertram; G Woodrow; R W Stephens
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines.

Authors:  J Felez; L A Miles; J Plescia; E F Plow
Journal:  J Cell Biol       Date:  1990-10       Impact factor: 10.539

7.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

8.  Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.

Authors:  Gillian E Stillfried; Darren N Saunders; Marie Ranson
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  Plasminogen receptors on rat colon carcinoma cells.

Authors:  M Durliat; O Komano; P Correc; O Bertrand; S Cochet; A Caignard; F Martin; P Burtin
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.